GeneSight: Helping Patients with Depression

Mental Health Month, Depression and GeneSight^® 



The GeneSight^® genetic test has produced exciting news for patients diagnosed with depression.  A landmark study showed that the GeneSight Test led to significant improvement in mental health outcomes for patients with major depressive disorder (MDD).  Read the full news release here.  This exciting, new data for GeneSight was presented at the 2018 American Psychiatric Association annual meeting.  The data that was presented showed that patients experienced 50% improvement in remission and 30% improvement in response for GeneSight, versus Treatment as Usual (TAU).

The 24-week landmark study included 1,167 patients with moderate-to-very severe depression who had failed at least one antidepressant medication.  Patients were divided into two treatment arms: the GeneSight Psychotropic test arm (n=560) in which clinicians used GeneSight test results to guide treatment decisions and a treatment-as-usual arm (n=607) in which psychiatrists and primary care physicians prescribed medication as they normally would without the benefit of genetic testing.

Take the next step with GeneSight   

“We now have the results from the largest-ever pharmacogenomics clinical study in patients with moderate-to-very severe depression,” said Bryan Dechairo, Ph.D., executive vice president of clinical development, Myriad Genetics. “The important news here is that when doctors used the GeneSight genetic test to guide their selection of antidepressants, patients experienced significantly higher rates of response and remission as well as better overall symptom relief.”

The GeneSight genetic test has helped thousands of people to find the right antidepressant medication that works for them.  Watch this video to learn more:

About GeneSight

GeneSight is a laboratory-developed pharmacogenomic test that uses cutting-edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSight report can help a clinician understand the way a patient’s unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual’s response to drug treatments, manufacturers’ FDA approved drug labels, peer reviewed scientific and clinical publications, and proven drug pharmacology. Quick turnaround time, combined with a customized report of the patient’s genomic makeup, clinical experience, and other factors can provide information to help a physician make personalized drug treatment choices for each patient. For more information about GeneSight, please visit www.genesight.com.